Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Skye Bioscience, Inc.SKYE · Entity 8098 | Director | March 31, 2026 | April 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Skye Bioscience, Inc.
Report date March 31, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.62 · Expires 2036-03-31 | Direct | 75,000 |
Reported balance
After 2026-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-31 · Grant · Acquired 75,000 · Balance 75,000 F1: The stock option vests in equal monthly installments over the one year period beginning March 31, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in equal monthly installments over the one year period beginning March 31, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2026 Filed Apr 2, 2026 18:15 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001628280-26-023346 · wk-form4_1775168112.xml · derivative · entry 1 Grayson Paul A. · CIK 0001861554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2036-03-31 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one year period beginning March 31, 2026. Read SEC document |
| February 06, 2026 Filed Feb 9, 2026 20:54 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001628280-26-006626 · wk-form4_1770688493.xml · derivative · entry 1 Grayson Paul A. · CIK 0001861554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-02-06 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one-year period beginning January 19, 2026. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 17:47 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001516551-25-000014 · wk-form4_1740610053.xml · derivative · entry 1 Grayson Paul A. · CIK 0001861554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2035-02-25 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one year period beginning February 21, 2025. Read SEC document |
| November 18, 2024 Filed Nov 19, 2024 21:14 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 86,244 | $4.99 | $430,357.56 |
DisclosureSEC source: 0001516551-24-000114 · wk-form4_1732068893.xml · nonDerivative · entry 2 Grayson Paul A. · CIK 0001861554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 259,701 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax obligations in connection with the vesting and settlement of performance-based restricted stock units. F2 · price: The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $4.98 to $5.08, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 21:14 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 307 | $5.55 | $1,703.85 |
DisclosureSEC source: 0001516551-24-000114 · wk-form4_1732068893.xml · nonDerivative · entry 1 Grayson Paul A. · CIK 0001861554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 345,945 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax obligations in connection with the vesting and settlement of performance-based restricted stock units. Read SEC document |
| October 28, 2024 Filed Oct 30, 2024 20:29 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $5.15 | $0.00 |
DisclosureSEC source: 0001516551-24-000099 · wk-form4_1730334553.xml · derivative · entry 1 Grayson Paul A. · CIK 0001861554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2034-10-27 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one year period beginning October 28, 2024. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 19:53 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001516551-24-000043 · wk-form4_1709600012.xml · derivative · entry 2 Grayson Paul A. · CIK 0001861554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-03-01 F3 · derivative.exercise_date: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the one year period beginning February 29, 2024. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 19:53 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001516551-24-000043 · wk-form4_1709600012.xml · nonDerivative · entry 1 Grayson Paul A. · CIK 0001861554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 346,252 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the following milestones: 25% vests upon achieving a market cap of $750M and a stock price of $20.00 per share, an additional 25% vests upon achieving a market cap of $1B and a stock price of $25.00 per share, an additional 25% vests upon achieving a market cap of $1.25B and a stock price of $30.00 per share, an additional 25% vest upon achieving a market cap of $1.5B or greater and a stock price of $35.00 per share; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs. Upon a change in control of the Issuer, 100% of the RSUs will become fully vested. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 06, 2023 Filed Nov 6, 2023 20:29 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantCommon Stock | 173,721 | $0.00 | $0.00 |
DisclosureSEC source: 0001516551-23-000093 · wk-form4_1699320557.xml · nonDerivative · entry 1 Grayson Paul A. · CIK 0001861554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 246,252 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the following performance milestones : 25% vests upon achieving a market cap of $125M, an additional 25% vests upon achieving a market cap of $250M, an additional 25% vests upon achieving a market cap of $400M, an additional 25% vest at an exit of $500M or greater; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs. Notwithstanding anything to the foregoing, all of the RSUS shall vest if an exit greater than $500M is achieved at an earlier date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 19:25 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantCommon Stock | 18,132,596 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001516551-23-000066 · wk-form4_1693351547.xml · nonDerivative · entry 1 Grayson Paul A. · CIK 0001861554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,132,596 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the following performance milestones : 25% vests upon achieving a market cap of $125M, an additional 25% vests upon achieving a market cap of $250M, an additional 25% vests upon achieving a market cap of $400M, an additional 25% vest at an exit of $500M or greater; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs . Notwithstanding anything to the foregoing, all of the RSUS shall vest if an exit greater than $500M is achieved at an earlier date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.